Last reviewed · How we verify
cyclosporine 0.05% ophthalmic emulsion
cyclosporine 0.05% ophthalmic emulsion is a Small molecule drug developed by Allergan. It is currently FDA-approved. Also known as: Restasis®, RESTASIS®, Restasis 0.05% ophthalmic emulsion.
At a glance
| Generic name | cyclosporine 0.05% ophthalmic emulsion |
|---|---|
| Also known as | Restasis®, RESTASIS®, Restasis 0.05% ophthalmic emulsion |
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA) (NA)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device (PHASE1, PHASE2)
- Effect of Cequa™ in Subjects With Dry Eye Disease (PHASE4)
- Novel Use of Restasis and PROSE Devices (PHASE3)
- Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients (PHASE4)
- Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclosporine 0.05% ophthalmic emulsion CI brief — competitive landscape report
- cyclosporine 0.05% ophthalmic emulsion updates RSS · CI watch RSS
- Allergan portfolio CI
Frequently asked questions about cyclosporine 0.05% ophthalmic emulsion
What is cyclosporine 0.05% ophthalmic emulsion?
cyclosporine 0.05% ophthalmic emulsion is a Small molecule drug developed by Allergan.
Who makes cyclosporine 0.05% ophthalmic emulsion?
cyclosporine 0.05% ophthalmic emulsion is developed and marketed by Allergan (see full Allergan pipeline at /company/allergan).
Is cyclosporine 0.05% ophthalmic emulsion also known as anything else?
cyclosporine 0.05% ophthalmic emulsion is also known as Restasis®, RESTASIS®, Restasis 0.05% ophthalmic emulsion.
What development phase is cyclosporine 0.05% ophthalmic emulsion in?
cyclosporine 0.05% ophthalmic emulsion is FDA-approved (marketed).
Related
- Manufacturer: Allergan — full pipeline
- Also known as: Restasis®, RESTASIS®, Restasis 0.05% ophthalmic emulsion
- Compare: cyclosporine 0.05% ophthalmic emulsion vs similar drugs
- Pricing: cyclosporine 0.05% ophthalmic emulsion cost, discount & access